Soluble IL-2R Levels Predict In-Hospital Mortality in COVID-19 Patients with Respiratory Failure
Overview
Authors
Affiliations
Acute respiratory distress syndrome is the primary cause of death in patients with coronavirus disease 2019 (COVID-19) pneumonia. Our study aims to determine the association between serum markers and mortality in COVID-19 patients with respiratory failure. This retrospective study was conducted in a tertiary care hospital in South Korea. Forty-nine patients with COVID-19, who required high flow nasal cannulation or mechanical ventilation from February 2020 to April 2021, were included. Demographic and laboratory data were analyzed at baseline and on Day 7 of admission. We found that serum creatinine, troponin, procalcitonin, and soluble interleukin-2 receptor (sIL-2R) at baseline were more elevated in the non-survivor group, but were not associated with mechanical ventilator use on Day 7. Older age, PaO/FiO ratio, lymphocyte and platelet counts, lactate dehydrogenase, IL-6, C-reactive protein, and sIL-2R on Day 7 were significantly associated with mortality. Delta sIL-2R (Day 7-Day 0) per standard deviation was significantly higher in the non-survivor group (adjusted hazard ratio 3.225, 95% confidence interval (CI) 1.151-9.037, = 0.026). Therefore, sIL-2R could predict mortality in COVID-19 patients with respiratory failure. Its sustained elevation suggests a hyper-inflammatory state, and mirrors the severity of COVID-19 in patients with respiratory failure, thereby warranting further attention.
Ji X, Guo Y, Tang L, Gao C J Inflamm Res. 2025; 18:3009-3024.
PMID: 40034687 PMC: 11874972. DOI: 10.2147/JIR.S504028.
Acute onset psychiatric diseases after SARS-CoV-2 virus infection among pediatric patients.
Yang L, Li J, Zhang D Front Neurol. 2024; 15:1445903.
PMID: 39445192 PMC: 11496280. DOI: 10.3389/fneur.2024.1445903.
Madhurantakam S, Karnam J, Muthukumar S, Prasad S Bioeng Transl Med. 2023; 8(5):e10566.
PMID: 37693054 PMC: 10486328. DOI: 10.1002/btm2.10566.
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes.
Dona A, Sanchez J, Palmer J, Synold T, Chiuppesi F, Thomas S J Immunol Sci. 2023; 7(1):9-27.
PMID: 36996290 PMC: 10042490. DOI: 10.29245/2578-3009/2023/1.1241.
Dhawan M, Rabaan A, Alwarthan S, Alhajri M, A Halwani M, Alshengeti A Vaccines (Basel). 2023; 11(3).
PMID: 36992283 PMC: 10059134. DOI: 10.3390/vaccines11030699.